Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil infusion for severe acute benzodiazepine toxicity
IRCT20120629010133N3Phase 3Completed
- Sponsor
- NIMAD
- Start
- May 2018
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of flumazenil in benzodiazepine overdose (2 arms), sponsored by NIMAD. Primary endpoints: Mortality, Complications during treatment and 1 more. Started May 2018; status: completed.
02
Drugs
flumazenil
03
Conditions
benzodiazepine overdose
Beyond the preview
Go deeper on IRCT20120629010133N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120629010133N3.